Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug...

Area of Science:

• Biochemistry
• Structural Biology
• Drug Discovery

Background:

• X-ray crystallography fuels protein structure determination for drug development.
• Thrombin inhibitors are crucial for antithrombotic drug discovery.
• Existing thrombin inhibitors often use arginine or benzamidine scaffolds.

Purpose of the Study:

• Expand the understanding of thrombin-inhibitor interactions.
• Investigate novel inhibitor classes beyond arginine and benzamidine.
• Characterize the structural basis of new thrombin inhibitor binding.

Main Methods:

• X-ray crystallography to determine protein-ligand complex structures.
• Analysis of protein and inhibitor conformations.
• Examination of hydrogen bonding and other non-covalent interactions.

Main Results:

• Determined structures of three new thrombin inhibitors: two 4-aminopyridine derivatives and one naphthamidine derivative.
• Observed significant protein main chain and side chain geometry changes upon inhibitor binding.
• Identified distinct binding modes for 4-aminopyridine inhibitors, including a novel peptide plane rotation and water-mediated interactions.
• Characterized the role of weak interactions, such as CH-O hydrogen bonds and pi-cloud interactions.
• Observed induced-fit conformational changes in the naphthamidine inhibitor complex.

Conclusions:

• Protein flexibility and water molecule dynamics are critical in protein-ligand interactions.
• Ligand design strategies must account for protein adaptability and water structure.
• The significance of weak interactions in binding mechanisms and crystallographic refinement should be emphasized.